Chondropathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Chondropathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of BP CC 001 stem cells from umbilical cord tissue for treating knee cartilage damage https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bp-cc-001-for-treating-knee-cartilage-damage-in-patients/ Wed, 29 Apr 2026 15:04:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-bp-cc-001-for-treating-knee-cartilage-damage-in-patients/ This study focuses on treating cartilage damage in the knee joint using a new medical product called BP CC 001. This product contains special cells called mesenchymal stem cells that are obtained from umbilical cord tissue. These cells are applied during surgery using a supportive structure called Chondro-Gide, which helps them stay in place in the damaged area of the knee.

The purpose of this study is to evaluate how safe and effective this new treatment is for repairing damaged knee cartilage. The treatment involves placing a specific amount of stem cells (10 million cells in 1 milliliter of solution) directly into the damaged area of the knee joint. This is done through a surgical procedure where the cells are carefully applied to the affected area.

During the study, patients will be monitored for two years after their surgery. Doctors will check how well the knee is healing and if there are any side effects from the treatment. They will evaluate various aspects of knee function, including pain levels, daily activities, and the quality of the newly formed cartilage tissue. Regular check-ups will help determine if the treatment is working as intended and ensure patient safety throughout the study period.

]]> Study on Autologous Chondrocytes and Remestemcel for Knee Cartilage Lesions in Patients with Symptomatic Articular Cartilage Damage https://clinicaltrials.eu/trial/study-on-autologous-chondrocytes-and-remestemcel-for-knee-cartilage-lesions-in-patients-with-symptomatic-articular-cartilage-damage/ Wed, 29 Apr 2026 15:02:15 +0000 https://clinicaltrials.eu/trial/study-on-autologous-chondrocytes-and-remestemcel-for-knee-cartilage-lesions-in-patients-with-symptomatic-articular-cartilage-damage/ This clinical trial is focused on studying a condition known as articular cartilage lesions of the knee. These lesions occur when the smooth cartilage that covers the ends of bones in the knee joint is damaged, leading to pain and difficulty in movement. The study is investigating a new treatment called the Instant MSC Product accompanying Autologous Chondron Transplantation (IMPACT). This treatment involves using a special paste made from a patient’s own cartilage cells, known as autologous chondrocytes, and a type of stem cell called remestemcel. The paste is applied directly to the damaged area in the knee through an injection.

The purpose of the study is to compare the effectiveness of the IMPACT treatment with standard care, which may include physical therapy and pain medication, but not surgery. Participants in the study will be randomly assigned to receive either the IMPACT treatment or the standard care. The study will follow participants over a period of 9 months to assess improvements in their knee function and overall quality of life. Participants will have check-ups at 3, 6, and 9 months to monitor their progress.

In addition to evaluating improvements in knee function and quality of life, the study will also look at how well the knee structure repairs itself after treatment. This will be done using MRI scans at 6 and 18 months after the treatment. The study aims to provide valuable information on whether the IMPACT treatment can offer better outcomes for patients with knee cartilage damage compared to the current standard care options.

]]> Study on the Effectiveness of Lenzumestrocel for Treating Knee Cartilage Defects in Patients https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lenzumestrocel-for-treating-knee-cartilage-defects-in-patients/ Wed, 29 Apr 2026 14:57:45 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-lenzumestrocel-for-treating-knee-cartilage-defects-in-patients/ This clinical trial is focused on studying the treatment of knee cartilage defects, which are injuries or damage to the smooth tissue that covers the ends of bones in the knee joint. The treatment being tested involves the use of a special type of cell therapy called lenzumestrocel, also known as BiCure ortho MSCp. These are stem cells derived from a patient’s own bone marrow, which are then expanded and used to help repair the damaged cartilage. The study aims to compare the effectiveness of this treatment when combined with a procedure called microfracture, which involves creating small holes in the bone to stimulate healing, and a 3D scaffold, which is a structure that supports the growth of new tissue.

The purpose of the study is to determine if the combination of microfracture, lenzumestrocel, and the 3D scaffold is more effective than using the microfracture and scaffold alone. Participants in the study will undergo surgery to treat their knee cartilage defects and will be monitored over a period of time to assess their recovery and the improvement in their knee function. The study will involve regular check-ups and assessments, including evaluations of knee function and pain levels, as well as imaging tests like MRI and X-rays to observe the healing process.

Throughout the study, participants will be observed for any side effects or adverse events related to the treatment. The study will last for several months, with key assessments taking place at different intervals, such as 3, 6, 12, and 24 months after the surgery. This will help researchers understand the long-term benefits and safety of using lenzumestrocel in treating knee cartilage defects.

]]>